For example, Tang et al. indicated that a positive association of genetic variants of ADIPOQ with prostate cancer was limited to persons who were overweight [42] and Petridou et al. showed that women with high BMI and low plasma ADIPOQ had 6.5–fold increased risk of endometrial cancer compared with women with normal BMI and higher ADIPOQ concentrations [43]. Here, ADIPOQ is linked to prostate carcinoma.